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Abstract
Background: Clobazam (CLB) is a well characterized antiepileptic drug (AED) that differs from other
benzodiazepines by its basic chemical structure and pharmacodynamic properties. Only one previous study
examined the efficacy of CLB as add-on therapy in refractory status epilepticus (RSE).
Methods: We analyzed RSE episodes treated in our institution between 2001 and 2012. Successful treatment with
CLB was scored if CLB was the last AED added to therapy before RSE termination. We assessed the differences
between patients with and without CLB and correlated CLB with outcome. Among patients treated with CLB, we
studied responders and non-responders and compared our CLB cohort with recently published data.
Results: CLB was part of the AED regimen in 24/70 (34.3 %) RSE episodes. In six of these (25.0 %) RSE resolution
was attributed to CLB. Baseline characteristics of episodes with and without CLB treatment showed no significant
differences and RSE termination rates were very similar (83.3 % vs. 80.4 %). CLB was administered in clinically more
complex RSE with longer RSE duration and worse outcome, but CLB was not related independently to outcome.
Comparison of our results with previously published data revealed that baseline characteristics as well as CLB
maintenance doses and time of treatment initiation were similar in both cohorts. CLB was less frequently the last
AED added to RSE therapy in our patients indicating a lower treatment success rate than previously reported.
Conclusions: CLB represents a reasonable AED and promising add-on agent for treatment of RSE. However, rates
of successful CLB response were substantially lower than in a recently published study. Differing RSE characteristics
and treatment strategies may account for the discrepancy between study results, as RSE etiologies and seizures
types associated with unfavorable prognosis were more common in our cohort, while anesthetics tended to be less
frequently applied to achieve seizure control.
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Background
Treatment of refractory status epilepticus (RSE) fre-
quently requires application of more than three antiepi-
leptic drugs (AEDs). As there is a limited number of
intravenous AEDs, orally administered AEDs represent a
therapeutic option particularly for longer RSE episodes
[1–3]. Recently, clobazam (CLB) has been associated
with high rates of RSE termination [4]. CLB is a well
characterized benzodiazepine with a unique chemical
structure and special pharmacodynamic properties.
While various studies investigated the efficacy of CLB
for treatment of refractory epilepsy, its potential in sta-
tus epilepticus (SE) and particularly RSE remains uncer-
tain [5]. We investigated the efficacy of CLB as add-on
treatment in RSE and compared results with those of a
recently published study.
Methods
Definition of refractory status epilepticus
SE was diagnosed on the basis of clinical and/or electro-
encephalographic evidence of seizure activity with a dur-
ation of at least 5 min, or of a series of seizures without
interictal clinical recovery [6]. RSE was defined as SE re-
fractory to administration of at least two properly dosed
AEDs [7, 8].
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Identification of RSE episodes and inclusion/exclusion
criteria
For identification of RSE episodes, we screened all
consecutive patients treated for SE between January
2001 and December 2012 by analyzing our institutional
databases including hospital records, clinical notes, and
EEG reports. RSE due to hypoxic brain damage was ex-
cluded as it was considered an entity of its own with a
particularly poor prognosis [9]. Furthermore, for reasons
of comparability with previous studies on RSE, simple-
partial and absence RSE episodes were excluded [7, 10].
Collection of clinical and RSE-specific data
We obtained demographic baseline characteristics, labora-
tory findings on hospital admission, RSE-specific informa-
tion, and data on treatment and complications. RSE
duration was defined as time from the onset of seizures
until termination, the latter being confirmed either elec-
troencephalographically or based on clinical improvement
arguing against ongoing seizure activity. RSE etiology was
assessed according to ILAE criteria (cryptogenic, acute,
remote, or progressive symptomatic) [11] and was consid-
ered potentially fatal when fulfilling the criteria proposed
by Rossetti and coworkers [12]. Clinical severity was
graded according to the Status Epilepticus Severity Score
(STESS) and RSE episodes were dichotomized into STESS
< 3 and STESS ≥ 3 [13]. For every AED administered, we
recorded the date of first application, the duration of treat-
ment, and the dosage. All AEDs used for RSE therapy (in-
cluding initial benzodiazepines as well as anesthetics)
were counted as contributing to the total number of
AEDs. In all episodes in which patients received CLB,
EEG data were reviewed and the episodes were grouped
into the following categories based on the findings on the
first EEG: +/− lateralized periodic discharges (LPD), +/−
lateralized seizure patterns or lateralized rhythmic delta
activity (RDA), +/− generalized periodic discharges (GPD),
generalized seizure patterns, or generalized RDA.
Outcome definition and assessment
The primary outcome measure was successful response to
CLB, defined as “CLB responders” if CLB was the last AED
added to treatment before RSE termination. The secondary
outcome measure was functional outcome at last available
follow-up. Functional outcome was assessed using the
modified Rankin Scale (mRS). Poor outcome was defined
when episodes either resulted in an mRS >2 or – in case of
a premorbid mRS between 3 and 5 – if there was further
functional decline, i.e. increase in the mRS.
Statistical analysis
We compared CLB responders and non-responders, pa-
tients treated with and without CLB, and our CLB co-
hort with the one reported by Sivakumar et al. [4].
Statistics were performed using SPSS Statistics 20.0
(www.spss.com). P values of 0.05 or less were considered
statistically significant and all tests were two-sided. For
assessment of frequency distributions of categorical vari-
ables, Pearson χ2 test, or where appropriate, Fisher’s
exact tests were applied. We used the Kolmogorov-
Smirnov test to distinguish between normal and non-
normal data distribution. Normally distributed data were
compared with the Student’s t-test, non-normally dis-
tributed data with the Mann-Whitney U test. In order to
identify independent predictors of outcome, all variables
significant on univariate analysis were entered into a for-
ward inclusion multivariable logistic regression model.
Parameters representing components of STESS were not
added separately into the model when the overall STESS
showed significant association upon univariate analysis.
Results
We identified 71 RSE episodes in 65 patients. We excluded
one episode because CLB treatment had been initiated be-
fore progression into RSE. Overall, RSE was treated with
CLB in 24/70 (34.3 %) episodes. CLB was initiated after a
median RSE duration of 2 days (IQR, 0–9 days) with a me-
dian maintenance dose of 20 mg/day (IQR, 14–23 mg/
day) and was applied for a median of 8 days (IQR, 5–13
days). Therapy was preceded by a median of 4 (IQR, 3–6)
other AEDs, while a median of 2 more AEDs (IQR, 0–4)
followed CLB.
CLB was the last AED added to therapy and – accord-
ing to the a priori definition – terminated RSE in 6/24
(25.0 %) episodes. Comparing CLB responders with non-
responders revealed a significantly higher rate of acute
symptomatic RSE etiology in non-responders, whereas
essentially all basic characteristics as well as EEG fea-
tures were similar among both groups (Table 1).
Table 2 summarizes demographics, clinical and RSE-
specific characteristics, as well as laboratory findings of
episodes treated with or without CLB. RSE termination
rates were not significantly different in patients treated
with (20/24; 83.3 %) or without (37/46; 80.4 %) CLB.
Therapy with CLB was associated with clinically more
complex RSE, significantly longer RSE durations, and
higher numbers of administered AEDs resulting in worse
functional long-term outcome (Table 2; poor outcome
CLB: 18/23 (78.3 %) vs. no CLB: 23/45 (51.1 %); p =
0.030). The median period from RSE resolution till last-
available follow-up was 12 weeks (IQR, 6–35) and
outcome was poor in 60.3 % of all episodes. Upon multi-
variable analysis, RSE duration (OR 1.10; 95 % CI: 1.00–
1.28; p = 0.044), sepsis (OR 10.2; 95 % CI: 1.25–82.46;
p = 0.030), and STESS ≥ 3 (OR 11.92; 95 % CI: 1.93–
73.56; p = 0.008) – but not use of CLB (OR 1.80;
95 % CI: 0.35–9.13; p = 0.481) – were independently
related to outcome.
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Table 1 Comparison of clobazam responders and non-responders
Variable Treated with CLB (n = 24) CLB responders (n = 6) CLB non-responders (n = 18) P value
Demographics
Gender, female 16 (66.7) 3 (50.0) 13 (72.2) 0.362b
Age on admission, y 64 (52–72) 70 (59–71) 64 (50–72) 0.820c
Age≥ 65 y 11 (45.8) 4 (66.7) 7 (38.9) 0.357b
Premorbid mRS 4 (1–4) 4 (4–5) 1 (1–4) 0.104c
RSE characteristics
NCSE in coma 4 (16.7) 1 (16.7) 3 (16.7) 1.000b
Generalized convulsive SE 8 (33.3) 3 (50.0) 5 (27.8) 0.362b
Complex-partial SE 12 (50.0) 2 (33.3) 10 (55.6) 0.640b
Stuporous or comatose 16 (66.7) 4 (66.7) 12 (66.7) 1.000b
Acute symptomatic etiology 10 (41.7) 0 (0) 10 (55.6) 0.024b
History of seizures 10 (41.7) 4 (66.7) 6 (33.3) 0.192b
Potentially fatal etiology 11 (45.8) 3 (50.0) 8 (44.4) 1.000b
STESS 3 (1–4) 3 (3–4) 3 (1–4) 0.537c
STESS≥ 3 15 (62.5) 5 (83.3) 10 (55.6) 0.351b
EEG features
Lateralized seizure patterns/RDA 9 (37.5) 2 (33.3) 7 (38.7) 1.000b
Lateralized periodic discharges 10 (41.7) 4 (66.7) 6 (33.3) 0.192b
Lateralized periodic discharges or seizure patterns/RDA 19 (79.2) 6 (100) 13 (72.2) 0.280b
Laboratory findings on admission
Leukocyte count, ×103/μl 8.5 (6.3–12.0) 8.5 (8.0–10.3) 8.8 (5.8–12.2) 0.914c
C-reactive protein, mg/l 18.0 (4.2–56.2) 3.4 (1.2–56.6) 33.0 (13.8–56.3) 0.446c
Hemoglobin, g/dl 11.2 (1.6) 10.9 (0.9) 11.3 (1.7) 0.622d
Serum sodium, mmol/l 136.5 (7.3) 136.8 (4.7) 136.4 (8.1) 0.908d
Treatment and complications
Duration of RSE, d 16 (8–32) 6 (4–36) 16 (10–27) 0.820c
Length of hospital stay, d 29 (13–61) 14 (6–53) 29 (14–57) 0.673c
Mechanical ventilation 13 (54.2) 3 (50.0) 10 (55.6) 1.000b
Length of mechanical ventilation, d 6 (0–43) 0 (0–30) 6 (0–48) 0.770c
Use of anesthetics 11 (45.8) 3 (50.0) 8 (44.4) 1.000b
Induction of burst suppression 11 (45.8) 3 (50.0) 8 (44.4) 1.000b
Number of AEDs 7 (5–11) 9 (5–14) 7 (4–11) 0.537c
Use of vasopressors 13 (54.2) 3 (50.0) 10 (55.6) 1.000b
Sepsis 8 (33.3) 3 (50.0) 5 (27.8) 0.362b
Outcome
RSE terminated 20 (83.3) 6 (100.0) 14 (77.8) 0.539b
Poor outcome at follow-upa 18 (78.3) 4 (80.0) 14 (77.8) 1.000b
In-hospital mortality 4 (16.7) 0 (0.0) 4 (22.2) 0.539b
Values are n (%), mean (±standard deviation) or median (interquartile range); significant (p < 0.05) parameters are expressed in bold
Abbreviations: AED antiepileptic drug, CLB clobazam, mRS modified Rankin Scale score, NCSE noncunvulsive status epilepticus, RDA rhythmic delta activity, RSE
refractory status epilepticus, SE status epilepticus, STESS Status Epilepticus Severity Score
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The comparison of our RSE patients treated with CLB
with those from the study by Sivakumar and coworkers
revealed no significant differences regarding patient age
and duration of hospital stay. In our cohort, a history of
seizures tended to be rarer and there was a trend toward
less frequent use of anesthetics. CLB maintenance doses
and days in RSE before initiation of CLB treatment were
similar, whereas CLB was the last AED added to therapy
in a significantly lower number of patients in our cohort
(Table 3).
Table 2 Comparison of episodes treated with and without clobazam
Variable Total cohort (n = 70) Treated with CLB (n = 24) Not treated with CLB (n = 46) P value
Demographics
Gender, female 47 (67.1) 16 (66.7) 31 (67.4) 0.951b
Age on admission, y 70 (49–78) 64 (52–72) 73 (45–80) 0.225d
Age≥ 65 y 41 (58.6) 11 (45.8) 30 (65.2) 0.118b
Premorbid mRS 3 (1–4) 4 (1–4) 3 (1–4) 0.694d
RSE characteristics
NCSE in coma 9 (12.9) 4 (16.7) 5 (10.9) 0.481c
Generalized convulsive SE 31 (44.3) 8 (33.3) 23 (50.0) 0.183b
Complex-partial SE 30 (42.9) 12 (50.0) 18 (39.1) 0.383b
Stuporous or comatose 44 (62.9) 16 (66.7) 28 (60.9) 0.634b
Acute symptomatic etiology 31 (44.3) 10 (41.7) 21 (45.7) 0.750b
History of seizures 37 (52.9) 10 (41.7) 27 (58.7) 0.175b
Potentially fatal etiology 31 (44.3) 11 (45.8) 20 (43.5) 0.851b
STESS 3 (2–4) 3 (1–4) 3 (2–4) 0.550d
STESS≥ 3 42 (60.0) 15 (62.5) 27 (58.7) 0.758b
Laboratory findings on admission
Leukocyte count, ×103/μl 9.4 (7.4–12.5) 8.5 (6.3–12.0) 10.1 (7.8–12.9) 0.197d
C-reactive protein, mg/l 15.7 (3.6–53.0) 18.0 (4.2–56.2) 8.3 (3.2–40.3) 0.273d
Hemoglobin, g/dl 11.7 (1.7) 11.2 (1.6) 11.9 (1.8) 0.110e
Serum sodium, mmol/l 136.9 (7.2) 136.5 (7.3) 137.2 (7.3) 0.704e
Treatment and complications
Duration of RSE, d 9 (4–17) 16 (8–32) 8 (4–14) 0.003d
Length of hospital stay, d 18 (10–30) 29 (13–61) 18 (10–29) 0.071d
Mechanical ventilation 44 (62.9) 13 (54.2) 31 (67.4) 0.277b
Length of mechanical ventilation, d 3 (0–16) 6 (0–43) 6 (0–15) 0.459d
Use of anesthetics 43 (61.4) 11 (45.8) 32 (69.6) 0.053b
Induction of burst suppression 28 (40.0) 11 (45.8) 17 (37.0) 0.472b
Number of AEDs 6 (5–8) 7 (5–11) 6 (5–8) 0.028d
Use of vasopressors 40 (57.1) 13 (54.2) 27 (58.7) 0.716b
Sepsis 19 (27.1) 8 (33.3) 11 (23.9) 0.400b
Outcome
RSE terminated 57 (81.4) 20 (83.3) 37 (80.4) 1.000c
Poor outcome at follow-upa 41 (60.3) 18 (78.3) 23 (51.1) 0.030b
In-hospital mortality 12 (17.1) 4 (16.7) 8 (17.4) 1.000c
Values are n (%), mean (±standard deviation) or median (interquartile range); significant (p < 0.05) parameters are expressed in bold, parameters showing a
statistical trend (p < 0.1) are expressed in italics
Abbreviations: AED antiepileptic drug, CLB clobazam, mRS modified Rankin Scale score, NCSE noncunvulsive status epilepticus, RSE refractory status epilepticus, SE
status epilepticus, STESS Status Epilepticus Severity Score
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Discussion
CLB has an interesting pharmacological profile and its
role in the treatment of refractory epilepsy is increas-
ingly studied [5]. The possibility of nasogastral tube ad-
ministration with excellent bioavailability [14] makes
CLB moreover an AED alternative worth considering in
RSE. In this study, we analyzed CLB for RSE and aimed
to compare our findings with recently published data.
We observed less convincing results regarding CLB effi-
cacy in seizure termination. As a consequence of differ-
ent definitions of CLB treatment success, however,
comparing our results with those of Sivakumar and co-
workers is difficult. In their study, the latter used a strict
definition only attributing RSE termination to CLB when
SE was terminated within 24 h of CLB administration
without changes in concurrent AEDs. Given that not all
of our patients were monitored with continuous EEG
and that we felt we could not with certainty exclude
modifications in co-administered AEDs in a retrospect-
ive approach, we chose to use a surrogate for successful
CLB treatment, i.e. whether CLB was the last AED
added to therapy before RSE termination. Sivakumar
and coworkers reported that CLB was the last AED
added in the vast majority of their cases. Compared to
our findings, this would equal a significantly higher rate
of successful CLB treatment according to our definition
(94.1 % vs. 25.0 %; p < 0.001) [4]. As dosing and timing
of CLB were similar in both studies, factors not directly
associated with CLB treatment seem to substantially
contribute to the discrepancies between study findings.
A history of seizures, for instance, tended to be rarer in
our cohort. As we furthermore excluded simple-partial
RSE from analysis, seizure types and RSE etiologies gen-
erally associated with a rather unfavorable prognosis
[15] were probably more common in our study popula-
tion. Despite this fact, the number of episodes treated
with anesthetics tended to be lower than in the study of
Sivakumar et al. which probably reflects diverse RSE
treatment strategies and again underscores the difficulty
of comparing the two studies.
Regarding our cohort, patients with and without CLB
were similar in their baseline characteristics, but there
were significant differences in RSE treatment-specific pa-
rameters such that CLB treated episodes appeared clinic-
ally more complex with longer RSE duration requiring
more AEDs. Furthermore, CLB therapy was overrepre-
sented in episodes in which the use of anesthetics was
avoided or postponed, presumably to prevent negative
side effects of therapeutic coma induction [16]. As far as
one can conclude from existing studies, including the
present one, it appears that CLB is rather applied in
more severe RSE and is currently not considered an
early choice AED [4]. Despite a comparatively low suc-
cess rate, initiation of CLB was still linked to RSE reso-
lution in some episodes and – in light of an
internalization of GABA receptors with prolonged seiz-
ure activity – CLB appears to still have effects despite
RSE refractoriness to benzodiazepines [17]. That we ob-
served no CLB responders among patients with acute
symptomatic RSE etiology may potentially suggest differ-
ent pathophysiological mechanisms involved.
The retrospective nature limits the interpretation of
our data and large confidence intervals reflect certain
data instability. Moreover, the small number of RSE epi-
sodes treated with CLB reduces the generalizability of
our findings. Not all of our patients received continuous
EEG monitoring; this may cause imprecision in the as-
sessment of time of RSE termination. Given the high
median number of AEDs applied, effects of AEDs other
than CLB in aborting seizures in our cohort cannot be
ruled out in those cases in which CLB was the last AED
added to therapy. We compared our patients with a co-
hort from a previous study which applied different cri-
teria for inclusion and assessment of treatment response.
The results of this analysis have therefore to be inter-
preted with due caution. We used the mRS for outcome
assessment. Given a high median premorbid mRS score
with some patients having 5 points already prior to ad-
mission, it is possible that in certain cases new deficits
caused by RSE may have not been reflected adequately.
Table 3 Comparison of clobazam treated patients from the study by Sivakumar et al. and the present study
Variable Sivakumar et al. (n = 17) Present study (n = 24) P value
Age on admission, y 63 (54–70) 64 (52–72) 0.466b
History of seizures 11 (64.7) 10 (41.7) 0.146a
CLB maintenance dose (mg/d) 20 (10–30) 20 (14–23) 0.763b
RSE duration before CLB, d 4 (2–7) 2 (0–9) 0.432b
CLB last AED added to therapy 16 (94.1) 6 (25.0) <0.001a
Use of anesthetics 12 (70.6) 11 (45.8) 0.116a
Length of hospital stay, d 30 (17–38) 29 (13–61) 0.672b
Values are n (%), or median (interquartile range); significant (p < 0.05) parameters are expressed in bold
Abbreviations: CLB clobazam, RSE refractory status epilepticus
aPearson χ2 test
bMann-Whitney U-test
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Conclusions
Even if we were unable to confirm the high rates of RSE
resolution reported, CLB remains an interesting AED
with evident effects on RSE. Despite CLB representing a
reasonable therapeutic option in RSE, based on present
data, rapid SE termination – if necessary with the use of
anesthetics – should not be delayed for treatment at-
tempts with CLB. Further studies using stronger statis-
tical designs are warranted to determine the clinical
efficacy of CLB in SE and RSE.
Abbreviations
AED: Antiepileptic drug; CI: Confidence interval; CLB: Clobazam;
EEG: Electroencephalography; IQR: Interquartile range; mRS: Modified Rankin
Scale; NCSE: Nonconvulsive status epilepticus; RSE: Refractory status
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